Unibest

Pharmaceutical intermediates

Pirtobrutinib Intermediates

4 pharmaceutical intermediates for Pirtobrutinib. Indication: Chronic lymphocytic leukemia; mantle cell lymphoma.

提交项目All intermediates

About Pirtobrutinib

Originator
Redx Pharma Ltd
Indication
Chronic lymphocytic leukemia; mantle cell lymphoma
Approved Date
01/27/2023
NCE Patent
01/27/2028
DS/DP
12/16/2036

Available intermediates

4 intermediates currently listed for Pirtobrutinib. Request specifications, documentation or a quotation for any item below.

Pirtobrutinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
methyl 4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]benzoate2182032-85-3//
4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]benzoic acid1571888-11-3//
N-(4-(2,2-dicyanoacetyl)benzyl)-5-fluoro-2- methoxybenzamide2819683-07-1//
N-[[4-(2,2-dicyano-1-methoxy-vinyl)phenyl]methyl]-5-fluoro-2-methoxy-benzamide2764851-04-7//

Other programs under P

PacritinibPalbociclibParecoxib sodiumParicalcitolPaxlovidPazopanib HydrochloridePeficitinib HydrobromidePemafibrate

Building toward Pirtobrutinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →